CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3557184
• 负责人: BRIAN LEYLAND-JONES
• 金额: $ 6.01万
• 依托单位: MCGILL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-07-15 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557184
• 关键词: Abelson leukemia virus; Hodgkin's disease; T lymphocyte; acute leukemia; antigen receptors; autologous transplantation; behavior test; bladder neoplasm; bone marrow transplantation; breast neoplasms; cancer information system; cell growth regulation; cell mediated lymphocytolysis test; colony stimulating factor; combination cancer therapy; cooperative study; cyclosporines; glutamates; glycosyltransferase; health behavior; hematopoietic stem cells; histocompatibility; human subject; human therapy evaluation; interleukin 2; lung neoplasms; lymphoma; messenger RNA; methotrexate; molecular cloning; molecular oncology; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer remission /regression; neoplasm /cancer surgery; neoplastic cell; nucleic acid probes; virus RNA

McGill University hospitals have participated in CALGB for the past 25 years. NCI funding for the past five years has permitted the establishment of an effective system of data collection throughout the five participating hospitals which is directed by the McGill Cancer Centre. This has coincided with increased activity at McGill in clinically directed research in neoplastic diseases. As the Group's activity shifted from passive contribution of protocol cases to participation in data evaluation and protocol generation some transient deterioration in case accrual occurred in 1986. This has been recognized and corrected. Accrual is now on target at an annualized rate of 140, due in part to the provision of adequate data collecting staff for the Queen Elizabeth and St. Mary's Hospitals during the past few months. McGill participating in the academic and administrative activities of CALGB has increased markedly over the past 5 years with representation on several core and on most of the administrative committees. We plan to extend our participation in the field of lymphoma and immunology. McGill has major immunology research projects in areas related to CALGB interest. Input into the planned bone marrow transplantation program will be significant as McGill is one of the leading marrow transplant centers in Canada and has had an active program during the past seven years in both autologous and allogeneic marrow transplantation. The many research projects under way at McGill in the oncology field provide a sound basis for increased scientific input into CALGB studies. These are detailed in the Institutional Profile.

麦吉尔大学医院过去曾参加过Calgb 25年。 过去五年来NCI资金允许 整个过程中建立有效的数据收集系统 由麦吉尔执导的五家参与医院 癌症中心。 这与活动的增加相吻合 McGill在临床上的肿瘤疾病研究中。 作为 该小组的活动从协议的被动贡献转移 参与数据评估和协议生成的案例 在1986年发生应计的情况下，某些瞬时恶化。 这已经得到认可和纠正。 应计目标 以140的年度汇率为140，部分原因是 伊丽莎白女王和圣女王的足够数据收集员工 玛丽的医院在过去几个月中。 麦吉尔参加 在Calb的学术和行政活动中 在过去的五年中，有明显增加 几个核心和大多数行政委员会。 我们计划扩大我们参与淋巴瘤和 免疫学。 麦吉尔在地区有主要的免疫学研究项目 与CALGB的兴趣有关。 输入计划的骨髓 移植计划将很重要，因为麦吉尔是 在加拿大领先的骨髓移植中心，并有活跃的 在过去的七年中，在自体和 同种异体骨髓移植。 许多研究项目 在肿瘤学领域的麦吉尔（McGill 增加了对CALB研究的科学意见。 这些是详细的 在机构概况中。